November 25, 2022

Is It Too Late to Buy Veru Stock?

After Veru (NASDAQ: VERU) got a thumbs-down from a nonbinding advisory committee at the Food and Drug Administration (FDA) on Nov. 9 regarding its drug sabizabulin for the treatment of severe COVID-19, shares of the company fell by more than 60%, and recovery is nowhere in sight.

This post was originally published on this site

Sign Up To Get FREE News, Tips and Offers!

X